Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
Go back to Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)| (NASDAQ: ACRS) | Delayed: 6.17 +0.22 (3.70%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.95 | 52 Week High | $33.88 | |||
| Open | $5.97 | 52 Week Low | $14.12 | |||
| Day High | $6.20 | P/E | N/A | |||
| Day Low | $5.87 | EPS | $0.00 | |||
| Volume | 1,746,646 | |||||
